{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:18:55Z","timestamp":1760782735670},"reference-count":16,"publisher":"Oxford University Press (OUP)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,6,1]]},"DOI":"10.1093\/jac\/dki119","type":"journal-article","created":{"date-parts":[[2005,4,23]],"date-time":"2005-04-23T00:25:23Z","timestamp":1114215923000},"page":"821-823","source":"Crossref","is-referenced-by-count":11,"title":["Switch strategies in patients on effective HAART"],"prefix":"10.1093","volume":"55","author":[{"given":"Franco","family":"Maggiolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diego","family":"Ripamonti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fredy","family":"Suter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2005,4,22]]},"reference":[{"key":"key\n\t\t\t\t20171010131739_R1","doi-asserted-by":"crossref","unstructured":"Dieleman JP, Sturkenboom MC, Wit FW et al. Low risk of treatment failure after substitution of nevirapine for protease inhibitors among human immunodeficiency virus-infected patients with virus suppression. J Infect Dis2002; 185: 1261\u20138.","DOI":"10.1086\/340131"},{"key":"key\n\t\t\t\t20171010131739_R2","doi-asserted-by":"crossref","unstructured":"Maggiolo F, Ripamonti D, Ravasio L et al. Outcome of 2 simplification strategies for the treatment of human immunodeficiency virus type 1 infection. Clin Infect Dis2003; 37: 41\u20139.","DOI":"10.1086\/375598"},{"key":"key\n\t\t\t\t20171010131739_R3","doi-asserted-by":"crossref","unstructured":"Bucher HC, Kofler A, Nuesch R et al. Meta-analysis of randomized controlled trials of simplified versus continued protease inhibitor-based antiretroviral therapy in HIV-1-infected patients. AIDS2003; 17: 2451\u20139.","DOI":"10.1097\/00002030-200311210-00007"},{"key":"key\n\t\t\t\t20171010131739_R4","doi-asserted-by":"crossref","unstructured":"Clumeck N, Goebel F, Rozenbaum W et al. Simplification with abacavir-based triple nucleoside therapy versus continued protease inhibitor-based highly active antiretroviral therapy in HIV-1-infected patients with undetectable plasma HIV-1 RNA. AIDS2001; 15: 1517\u201326.","DOI":"10.1097\/00002030-200108170-00009"},{"key":"key\n\t\t\t\t20171010131739_R5","doi-asserted-by":"crossref","unstructured":"Ruiz L, Negredo E, Domingo P et al. Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy. 1-year prospective follow-up of a multicenter, randomized, controlled study. J Acquir Immune Defic Syndr2001; 27: 229\u201336.","DOI":"10.1097\/00042560-200107010-00003"},{"key":"key\n\t\t\t\t20171010131739_R6","doi-asserted-by":"crossref","unstructured":"Carr A, Hudson J, Chuah J et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study. AIDS2001; 15: 1811\u201322.","DOI":"10.1097\/00002030-200109280-00010"},{"key":"key\n\t\t\t\t20171010131739_R7","doi-asserted-by":"crossref","unstructured":"Martinez E, Arnaiz JA, Podzamczer D et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med2003; 349: 1036\u201346.","DOI":"10.1056\/NEJMoa021589"},{"key":"key\n\t\t\t\t20171010131739_R8","doi-asserted-by":"crossref","unstructured":"Estrada V, de Villar N G P, Martinez Larrad MT et al. Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clin Infect Dis2002; 35: 69\u201376.","DOI":"10.1086\/340863"},{"key":"key\n\t\t\t\t20171010131739_R9","doi-asserted-by":"crossref","unstructured":"Opravil M, Hirschel B, Lazzarin A et al. A randomized trial of simplified maintenance therapy with abacavir, lamivudine and zidovudine in human immunodeficiency virus infection. J Infect Dis2002; 185: 1251\u201360.","DOI":"10.1086\/340312"},{"key":"key\n\t\t\t\t20171010131739_R10","doi-asserted-by":"crossref","unstructured":"Katlama C, Fenske S, Gazzard B et al. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med2003; 4: 79\u201386.","DOI":"10.1046\/j.1468-1293.2003.00139.x"},{"key":"key\n\t\t\t\t20171010131739_R11","doi-asserted-by":"crossref","unstructured":"Molina JM, Journot V, Morand-Joubert L et al. Simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial. J Infect Dis2005; 191: 830\u20139.","DOI":"10.1086\/428091"},{"key":"key\n\t\t\t\t20171010131739_R12","doi-asserted-by":"crossref","unstructured":"Stone VE, Jordan J, Tolson J et al. Perspectives on adherence and simplicity for HIV-infected patients on antiretroviral therapy: self-report of the relative importance of multiple attributes of highly active antiretroviral therapy (HAART) regimens in predicting adherence. J Acquir Immune Defic Syndr2004; 36: 808\u201316.","DOI":"10.1097\/00126334-200407010-00007"},{"key":"key\n\t\t\t\t20171010131739_R13","doi-asserted-by":"crossref","unstructured":"Maggiolo F, Ravasio L, Ripamonti D et al. Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors. Clin Infect Dis2005; 40: 158\u201363.","DOI":"10.1086\/426595"},{"key":"key\n\t\t\t\t20171010131739_R14","doi-asserted-by":"crossref","unstructured":"Carr A, Workman C, Smith DE et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA2002; 288: 207\u201315.","DOI":"10.1001\/jama.288.2.207"},{"key":"key\n\t\t\t\t20171010131739_R15","doi-asserted-by":"crossref","unstructured":"McComsey GA, Ward DJ, Hessenthaler SM et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis2004; 38: 263\u201370.","DOI":"10.1086\/380790"},{"key":"key\n\t\t\t\t20171010131739_R16","doi-asserted-by":"crossref","unstructured":"De Jesus E, Herrera G, Teofilo J et al. Abacavir versus zidovudine combined with lamivudine and efavirenz for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis2004; 39: 1038\u201346.","DOI":"10.1086\/424009"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/55\/6\/821\/2155313\/dki119.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,7]],"date-time":"2020-04-07T01:57:36Z","timestamp":1586224656000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/jac\/article\/55\/6\/821\/725518\/Switch-strategies-in-patients-on-effective-HAART"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,4,22]]},"references-count":16,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2005,4,22]]},"published-print":{"date-parts":[[2005,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dki119","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2005,6]]},"published":{"date-parts":[[2005,4,22]]}}}